Celebrating 10 Years of Residency Program Excellence
2023 is a year of celebration at Navitus. Not only is it the 20th anniversary of our founding, but 2023 also marks 10 years of Navitus' residency...
2023 is a year of celebration at Navitus. Not only is it the 20th anniversary of our founding, but 2023 also marks 10 years of Navitus' residency...
Our recent August Pharmacy and Therapeutics (P&T) Committee meeting reviewed the release of various Humira® biosimilars. Staying true to our...
In an ever-changing legislative landscape, we want to help our clients and partners stay informed of the latest happenings and how proposed policies...
This summer has seen a continuation of the long-awaited market entry of Humira® (adalimumab) biosimilars. As of July 1, nine additional biosimilars...
We are pleased to share our 2022 Drug Trend Report with you. This year's report highlights our success in managing pharmacy benefit costs for our...
We had the pleasure of connecting with our new Chief Financial Officer, George Hepburn, to discuss what excites him about his new role, what inspires...
We recently sat down with Ken Goodnight to discuss his key priorities as Chief Transformation & Digital Officer and to learn about his professional...
The market entry of biosimilars to Humira® (adalimumab) is long-awaited. These products have the potential to improve affordability in the near- and...
As we enter 2023, David Fields is sharing his top forecasts and takeaways for plan sponsors and the PBM industry.
As we continue our employee spotlight series, we are excited to highlight Shelly McAdoo, Navitus’ new Diversity, Equity and Inclusion (DEI) Senior...
Navitus’ Vice President of Government Relations, Robyn Crosson, shares her insight into the Inflation Reduction Act and how it will impact our...
This week we provide an overview of our 2021 drug trend and client savings with insights for 2022 and beyond.
Copyright © 2022 Navitus
All rights reserved